RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe …
Full RDHL analysis →
Competitive advantage assessment
Key risks
ROIC Below WACC or PeersROIC at 8.5th percentile suggests inefficient capital deployment.
Below-Peer Operating EfficiencyOperating margin at 8.8th percentile indicates below-peer efficiency.
The dashed ring is the peer median. Defense scores are percentile ranks
against peers, so 50 is roughly the typical company in this group.
Upgrade to unlock the signals and evidence behind each defense.
Premium access
Unlock full defense analysis
Get key signals, strengths, and risks for every moat dimension.
Where RDHL ranks in Drug Manufacturers - Specialty & Generic
Redhill Biopharma Ltd. ranks #81 of 91
scored companies in Drug Manufacturers - Specialty & Generic by moat score — the top 89%.
The widest moat in the group is Zoetis Inc. (ZTS)
at 85/100.
Moat scores for companies ranked near RDHL in Drug Manufacturers - Specialty & Generic
Pricing power is the ability to raise prices without losing volume.
Cost Advantage
Score 8
· 15% of the moat score
A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.
Customer Stickiness
Score 9
· 15% of the moat score
Stickiness is what makes revenue repeat without being re-won every year.
Capital Efficiency
Score 4
· 18% of the moat score
Capital efficiency asks what the company earns on the money tied up in the business.
Resilience
Score 27
· 17% of the moat score
Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.
Scale & Market Position
Score 17
· 15% of the moat score
Scale matters only when it converts into economics.
Redhill Biopharma Ltd. (RDHL) scores 12 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as weak. It ranks #81 of 91 scored companies in Drug Manufacturers - Specialty & Generic, the top 89%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 90 companies in Drug Manufacturers - Specialty & Generic. Its strongest defense is Resilience (27/100) and its weakest is Capital Efficiency (4/100).
How does Redhill Biopharma Ltd. compare with other Drug Manufacturers - Specialty & Generic companies?
Redhill Biopharma Ltd. ranks #81 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score. The widest moat in Drug Manufacturers - Specialty & Generic is Zoetis Inc. (ZTS) at 85/100. The companies ranked closest are Talphera, Inc. (TLPH) at 13 just above it and PainReform Ltd. (PRFX) at 9 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 90 companies in Drug Manufacturers - Specialty & Generic. The defenses are then weighted to produce the overall score out of 100.
Why is Redhill Biopharma Ltd. scored with the Corporate Default template?
Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.
Which competitive defenses are measured for Redhill Biopharma Ltd.?
The Corporate Default template measures 6 defenses, and RDHL scores: Pricing Power (10), Cost Advantage (8), Customer Stickiness (9), Capital Efficiency (4), Resilience (27), Scale & Market Position (17). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.